睿知中国医院研究地图
候选清单

正在招募冠心病IV期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

ClinicalTrials.gov 上登记的一项冠心病开放试验,由北京协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京协和医院Peking Union Medical College Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT03378934,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 2

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(2 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL.

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT03378934,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Provision of written informed consent.
  2. Aged 18-70 years, male or female.
  3. Currently, > 8 but ≤ 40 weeks after index percutaneous coronary intervention (PCI) .
  4. Receiving dual antiplatelet therapy (DAPT) with aspirin (Bayaspirin TM) 100 mg once daily and clopidogrel (Plavix TM) 75 mg once daily for ≥ 7 days.
  5. No cardiac ischemic events or bleeding events occurred after the index PCI.
  6. Cardiac ischemic events include myocardial infarction, coronary revascularization, and definite or probable stent thrombosis;
  7. Bleeding events include major or minor bleeding according to the Platelet Inhibition and Patient Outcomes (PLATO) definition.
  8. PRECISE-DAPT score < 25 evaluated after the index PCI and before the index hospital discharge.
  9. Females who are either post-menopausal > 1 year or surgically sterile.

排除标准:Exclusion Criteria:

  1. Use of berberine within 30 days of screening.
  2. Use of any fibrinolytic or antithrombotic agents, with the exception of aspirin and clopidogrel, within 30 days of screening.
  3. Any indications other than coronary artery disease (e.g., atrial fibrillation, prosthetic heart valve, venous thromboembolism, ventricular thrombosis, et al) for fibrinolytic or antithrombotic treatment during the study period.
  4. Planned use of berberine, as well as any fibrinolytic or antithrombotic agents, with the exception of aspirin (Bayaspirin TM) and clopidogrel (Plavix TM), during the study period.
  5. Planned use of moderate or strong cytochrome P450 (CYP) 2C19 inhibitors, CYP2C19 substrates with narrow therapeutic index, or strong CYP2C19 inducers during the study period.
  6. Planned coronary revascularization, including PCI and coronary artery bypass graft (CABG) during the study period.
  7. Increased bleeding risk, including
  8. any history of intracranial, intraocular, retroperitoneal, or spinal bleeding;
  9. recent (within 30 days of screening) gastrointestinal (GI) bleeding;
  10. recent (within 30 days of screening) major trauma or major surgery;
  11. planned surgery or other invasive procedure during the study period;
  12. sustained uncontrolled hypertension (systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure [DBP] > 100 mmHg);
  13. history of hemorrhagic disorders, e.g., haemophilia, von Willebrand's disease;
  14. inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during the study period;
  15. platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL.
  16. Contraindications for aspirin, clopidogrel, and berberine, e.g., hypersensitivity, active bleeding, bleeding diathesis, coagulation disorders, severe liver or kidney diseases, hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, et al.
  17. History of intolerance to aspirin, clopidogrel, and berberine.
  18. Any condition, which in the opinion of the Investigator, would make it unsuitable for the patient to participate in this study. For example, conditions which may put the patient at risk, e.g., liver or kidney dysfunction, et al; or increase the risk of non-compliance to study protocol or follow-up, e.g., history of drug addiction or alcohol abuse, et al; or influence the result of the study, e.g., active cancer, et al.
  19. Patients who has previously been randomized in this study.
  20. Participation in another investigational drug or device study within 30 days of screening.
  21. Involvement in the planning and conduct of the study (applies to investigators, contract research organization staff, and study site staff, et al).

引自 ClinicalTrials.gov, NCT03378934, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT03378934,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT03378934